Rucaparib (re-assessment: ovarian, fallopian tube or primary peritoneal cancer, maintenance therapy)

Subject:

• Active Substance: Rucaparib
• Name: Rubraca®
• Therapeutic area: Ovarian, fallopian tube or primary peritoneal cancer
• Pharmaceutical company: Clovis Oncology Germany GmbH

Time table:

• Start: 01.04.2023
• Final decision by G-BA: 21.09.2023

Final decision:

• No additional benefit proved